Posts Tagged ‘2022’

In this past year, we emerged from the isolation of COVID-19 thanks in no small part to the heroic work of the life sciences industry in developing vaccines, rapid tests and new treatments that have made the pandemic much more manageable. In spite of this success, we have faced tremendous pressure at the federal level with threats to intellectual property, the lifeblood of the industry, and a push to insert price controls with potential repercussions on innovation.